caa a22 4500 47578667X CHVBK 20180406123700.0 cr unu---uuuuu 170329e20000701xx s 000 0 eng 10.1007/s004310000495 doi (NATIONALLICENCE)springer-10.1007/s004310000495 Preliminary experience with the angiotensin II receptor antagonist irbesartan in chronic kidney disease [Elektronische Daten] [Rodo O. von Vigier, Priska M. Zberg, Oliver Teuffel, Mario G. Bianchetti] Blocking the formation of angiotensin II with converting enzyme inhibitors is an established intervention for kidney disease. The advent of antagonists of the angiotensin II receptor has increased the options for inhibiting the renin-angiotensin-aldosterone system. In adults, angiotensin II antagonists have antihypertensive and antiproteinuric effects similar to those of converting enzyme inhibitors and an adverse effect profile similar to that of placebo. In children, no information is available on angiotensin II antagonists. A total of 20 children (aged 4 to 17 years) with chronic kidney disease received the angiotensin II antagonist irbesartan given once daily. They had hypertension (n=11), overt proteinuria (n=3), or both (n=6). At last follow-up, 2 to 17 months after starting irbesartan (median dosage: 3.3 mg/kg body weight daily), arterial pressure was significantly reduced: the systolic value by 16 [6-22] and the diastolic value by 11 [4-22] mmHg (median and interquartile range). In nine patients with proteinuria, the urinary albumin/creatinine ratio significantly decreased by 145 [105-209] mg/mmol. The frequency of reported adverse events was similar before and with irbesartan. Conclusion In children with chronic kidney disease the effects of the angiotensin II antagonist irbesartan on arterial pressure and proteinuria mimic those observed with the converting enzyme inhibitors. The effectiveness of a single daily dose and the paucity of side-effects suggest that angiotensin II antagonists expand therapeutic options for inhibiting the renin-angiotensin-aldosterone system in children. Springer-Verlag Berlin Heidelberg, 2000 Key words Angiotensin II antagonist nationallicence Hypertension nationallicence Irbesartan nationallicence Kidney disease nationallicence Proteinuria nationallicence von Vigier Rodo O. Department of Paediatrics, University of Bern, Inselspital, 3010 Bern, Switzerland e-mail: mario.bianchetti@insel.ch, CH aut Zberg Priska M. Department of Paediatrics, University of Bern, Inselspital, 3010 Bern, Switzerland e-mail: mario.bianchetti@insel.ch, CH aut Teuffel Oliver Department of Paediatrics, University of Bern, Inselspital, 3010 Bern, Switzerland e-mail: mario.bianchetti@insel.ch, CH aut Bianchetti Mario G. Department of Paediatrics, University of Bern, Inselspital, 3010 Bern, Switzerland e-mail: mario.bianchetti@insel.ch, CH aut https://doi.org/10.1007/s004310000495 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s004310000495 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- von Vigier Rodo O. Department of Paediatrics, University of Bern, Inselspital, 3010 Bern, Switzerland e-mail: mario.bianchetti@insel.ch, CH aut NATIONALLICENCE 700 1- Zberg Priska M. Department of Paediatrics, University of Bern, Inselspital, 3010 Bern, Switzerland e-mail: mario.bianchetti@insel.ch, CH aut NATIONALLICENCE 700 1- Teuffel Oliver Department of Paediatrics, University of Bern, Inselspital, 3010 Bern, Switzerland e-mail: mario.bianchetti@insel.ch, CH aut NATIONALLICENCE 700 1- Bianchetti Mario G. Department of Paediatrics, University of Bern, Inselspital, 3010 Bern, Switzerland e-mail: mario.bianchetti@insel.ch, CH aut Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer